These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28458511)

  • 1. Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension.
    Tamçelik N; Izgi B; Temel A; Yildirim N; Okka M; Özcan A; Yüksel N; Elgin U; Altan Ç; Ozer B
    Clin Ophthalmol; 2017; 11():723-731. PubMed ID: 28458511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
    Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
    BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting.
    Kook MS; Simonyi S; Sohn YH; Kim CY; Park KH
    Jpn J Ophthalmol; 2015 Sep; 59(5):325-34. PubMed ID: 26202440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension.
    Sun X; Yao K; Liu Q; Zhang H; Xing X; Fang A; Duan X; Yu M; Chen MY; Yang J; Goodkin ML
    Ophthalmol Ther; 2023 Feb; 12(1):341-353. PubMed ID: 36370233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study.
    Feuerhake C; Buchholz P; Kimmich F
    Curr Med Res Opin; 2009 Apr; 25(4):1037-43. PubMed ID: 19290780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
    Nakano T; Mizoue S; Fuse N; Iwase A; Matsumoto S; Yoshikawa K
    Adv Ther; 2015 Sep; 32(9):823-37. PubMed ID: 26424331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension.
    Pfennigsdorf S; Ramez O; von Kistowski G; Mäder B; Eschstruth P; Froböse M; Thelen U; Spraul C; Schnober D; Cooper H; Laube T
    Clin Ophthalmol; 2012; 6():739-46. PubMed ID: 22654501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB; Hubatsch DA
    BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension.
    Stevens A; Iliev ME; de Jong L; Grobeiu I; Hommer A
    Clin Ophthalmol; 2016; 10():635-41. PubMed ID: 27103783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimatoprost/timolol fixed combination (BTFC) in patients with primary open angle glaucoma or ocular hypertension in Greece.
    Rotsos TG; Kliafa VG; Asher KJ; Papaconstantinou D
    Int J Ophthalmol; 2016; 9(1):69-75. PubMed ID: 26949613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol in Glaucoma and Ocular Hypertension in India: A Multicenter, Open-Label, Phase 3 Study.
    Menon MG; Goodkin ML
    Clin Ophthalmol; 2022; 16():3559-3569. PubMed ID: 36274674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study.
    Vetrugno M; Cardascia N; Cantatore F; Sborgia C
    Curr Ther Res Clin Exp; 2004 Nov; 65(6):444-54. PubMed ID: 24672097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice.
    Pillunat LE; Eschstruth P; Häsemeyer S; Thelen U; Foja C; Leaback R; Pfennigsdorf S
    Clin Ophthalmol; 2016; 10():1759-65. PubMed ID: 27672307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
    Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
    Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Pfennigsdorf S; de Jong L; Makk S; Fournichot Y; Bron A; Morgan-Warren RJ; Maltman J
    Clin Ophthalmol; 2013; 7():1219-25. PubMed ID: 23814459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Open-Angle Glaucoma and Ocular Hypertension with the Fixed-Dose Combination of Preservative-Free Tafluprost/Timolol: Clinical Outcomes from Ophthalmology Clinics in Italy.
    Oddone F; Scorcia V; Iester M; Sisto D; De Cilla S; Bettin P; Cagini C; Figus M; Marchini G; Rossetti L; Rossi G; Salgarello T; Scuderi GL; Staurenghi G;
    Clin Ophthalmol; 2022; 16():1707-1719. PubMed ID: 35677639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.